ASP Isotopes Inc. Common Stock
NASDAQ:ASPIChemicals
+$0.32 today
- Market cap
- $191.68M
- Beta
- 3.44
- P/E (TTM)
- -4.9
- EPS (TTM)
- -$1.43
Volume 7.05M
Average 5.68M
ASPI EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
ASP Isotopes Inc. Common StockNASDAQ: ASPI
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$21.83M, compared with -$8.3M a year earlier. Trailing-twelve-month EBITDA was -$170.61M.
Context
- EBITDA amounted to 658.6% of revenue in FY2025, down 103.5 pp from a year earlier.
- EBITDA grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 2 analysts of -$34.74M (+77.9%) for the fiscal year ending Dec 2026, a step up from the -397.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$21.83M+64.8% QoQ
- Last fiscal yearDec 2025
- -$157.07M-397.4% YoY
- LTMMar 2026
- -$170.61M-417.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -163.2% | +71.3% | +234.4 pp |
| 1 year | -397.4% | +77.9% | +475.2 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (157.07M) USD
- Year-over-year change
- -397.4%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (157.07M) | -397.4% |
| FY2024 | 2024-12-31 | (31.58M) | -95.6% |
| FY2023 | 2023-12-31 | (16.14M) | -231.3% |
| FY2022 | 2022-12-31 | (4.87M) | -88.2% |
| FY2021 | 2021-12-31 | (2.59M) | — |
EBITDA vs competitors
How ASPI compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -417.3% is the 10th highest of 11, against a peer median of -9.0%.
- EBITDA amounts to 633.6% of revenue for ASPI, versus a peer median of 13.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | R$6.93B BRL | +2564.8% | -57.3% | 10.4% | |
| LTM Mar 2026 | $466.81M USD | +8.6% | -1.5% | 37.8% | |
| LTM Mar 2026 | $201.6M USD | +153.9% | -11.1% | 15.6% | |
| LTM Mar 2026 | $143.17M USD | +374.2% | +5.5% | 7.4% | |
| LTM Mar 2026 | $139.93M USD | -27.5% | -10.3% | 6.0% | |
| LTM Apr 2026 | $88.81M USD | +1.7% | +64.4% | 18.1% | |
| LTM Mar 2026 | $66M USD | -84.7% | -57.7% | 2.3% | |
| LTM Mar 2026 | -$18.43M USD | -5335.6% | — | 47.2% | |
| LTM Mar 2026 | -$58.28M USD | -19.7% | — | 4.2% | |
| LTM Mar 2026 | -$170.61M USD | -417.3% | — | 633.6% | |
| LTM Mar 2026 | -$206.47M USD | -102.0% | — | 154.6% | |
| Peer median (excluding ASPI) | — | -9.0% | -10.3% | 13.0% | |
Competitors are the stored peer set for ASPI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 433.03K | 4.14M | 23.85M |
| Cost of Revenue | 19.38K | 0 | 294.06K | 2.55M | 20.44M |
| Gross Profit | (19.38K) | 0 | 138.97K | 1.6M | 3.41M |
| Gross Margin | — | — | 32.1% | 38.6% | 14.3% |
| Research & Development | 41.61K | 1.27M | 764.58K | 3.14M | 12.36M |
| Selling, General & Admin | 2.55M | 3.83M | 15.42M | 24.81M | 48.24M |
| Operating Expenses | 2.59M | 5.1M | 16.18M | 27.95M | 60.6M |
| Depreciation & Amortization | 19.38K | 72.57K | 37.43K | 471K | 1.91M |
| EBITDA | (2.59M) | (4.87M) | (16.14M) | (31.58M) | (157.07M) |
| EBITDA Margin | — | — | -3728.2% | -762.1% | -658.6% |
| Operating Income | (2.61M) | (5.1M) | (16.04M) | (26.35M) | (57.19M) |
| Operating Margin | — | — | -3704.6% | -636.0% | -239.8% |
| Interest Income | 115 | 3.38K | 9.07K | 1.24M | 6.79M |
| Interest Expense | 0 | 0 | 118.55K | 258.87K | 575K |
| Other Income / Expenses | 113 | 153.91K | (258.26K) | (5.96M) | (102.37M) |
| Income Before Tax | (2.61M) | (4.95M) | (16.3M) | (32.31M) | (159.56M) |
| Pre-Tax Margin | — | — | -3764.3% | -779.7% | -669.0% |
| Income Tax Expense | 0 | 0 | (6.13K) | 111.45K | 282K |
| Net Income | (2.61M) | (4.95M) | (16.29M) | (32.33M) | (175.09M) |
| Net Margin | — | — | -3761.0% | -780.3% | -734.2% |
| EPS (Basic) | (0.08) | (0.13) | (0.49) | (0.63) | (2.11) |
| EPS (Diluted) | (0.08) | (0.13) | (0.49) | (0.63) | (2.11) |
| Weighted Avg Shares | 34.36M | 35.91M | 33.07M | 55.67M | 83.01M |
| Weighted Avg Shares (Diluted) | 34.36M | 35.91M | 33.07M | 55.67M | 83.01M |
ASP Isotopes Inc. Common Stock
NASDAQ:ASPI
Intrinsic Alpha fair value
Locked
Current Price
$1.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.